On August 2, at 7:00 AM, at a special breakfast, Dr. Brandy Wilkinson, JAX® In Vivo Pharmacology Study Director, will give a presentation on the new JAX Cancer Consortium for Patient-Derived Xenografts (PDX). Developed in collaboration with UC Davis Cancer Center, Sacramento, CA, the Swedish Hospital, Seattle, WA, the Scripps Research Institute, La Jolla, CA, and UC San Diego Moores Cancer Center, the Consortium has created patient-derived xenograft models using NOD scid IL2 receptor gamma chain knockout (NSG) mice as hosts. Scientists will be able to use the models to support large-scale basic and preclinical cancer research.
On the same day, at 12:00 PM, at a special luncheon, a cadre of JAX scientists will facilitate round table discussions on three cutting-edge humanized mouse models: PDX, NSG, and FcRn. By overcoming species-specific differences between mice and humans, these models are more clinically relevant and more predictive of candidate drug efficacy than conventional models. JAX scientists will explain how these models can speed up drug discovery programs in antibody engineering, autoimmune diseases, hematopoiesis, infectious diseases, oncology, and other areas. To kick off the discussions, Yan Yang, Ph.D., head of JAX® In Vivo Pharmacology Services, will briefly highlight the models and introduce the subject matter experts. Leon Hall, Ph.D., JAX® In Vivo Pharmacology Program Director, will facilitate discussions on humanized NSG (hNSG) – immunodeficient NSG mice engrafted with a human immune system. Brandy Wilkinson, Ph.D., JAX® In Vivo Pharmacology Study Director, will facilitate discussions on PDX models – immunodeficient NSG mice engrafted with passaged human tumor tissues. And, Gabriele Proetzel, Ph.D., Associate Director of Technology Transfer at JAX, will facilitate discussions on humanized FcRn mice – mice that express human FcRn receptor to support human antibody PK studies.
Space for these events is limited. Register today at www.jax.org/jaxmice/events/2011/drugdiscovery-rsvp).
